Rubius Therapeutics - RUBY Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RUBY shares.
View RUBY analyst ratings or view top-rated stocks.

4 equities research analysts have issued twelve-month price objectives for Rubius Therapeutics' shares. Their RUBY share price forecasts range from $3.00 to $8.00. On average, they expect the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 525.1% from the stock's current price.
View analysts price targets for RUBY or view top-rated stocks among Wall Street analysts.

Rubius Therapeutics' stock was trading at $9.68 at the beginning of the year. Since then, RUBY shares have decreased by 91.7% and is now trading at $0.7999.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our RUBY earnings forecast.

Rubius Therapeutics, Inc. (NASDAQ:RUBY) announced its earnings results on Monday, November, 8th. The company reported ($0.55) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.01. During the same period in the prior year, the company posted ($0.51) earnings per share.

12 employees have rated Rubius Therapeutics Chief Executive Officer Pablo Cagnoni on Glassdoor.com. Pablo Cagnoni has an approval rating of 91% among the company's employees. This puts Pablo Cagnoni in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Rubius Therapeutics investors own include Sorrento Therapeutics (SRNE), Marinus Pharmaceuticals (MRNS), Xeris Biopharma (XERS), Fulcrum Therapeutics (FULC), Recro Pharma (REPH), TG Therapeutics (TGTX), Tilray (TLRY), Viking Therapeutics (VKTX), ADMA Biologics (ADMA) and Adverum Biotechnologies (ADVM).

(RUBY) raised $200 million in an initial public offering on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Rubius Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.92%), State of Michigan Retirement System (0.73%), JPMorgan Chase & Co. (0.62%), Connor Clark & Lunn Investment Management Ltd. (0.39%), Northern Trust Corp (0.08%) and LPL Financial LLC (0.07%). Insiders that own company stock include Christina M Coughlin, Christopher L Carpenter, Dannielle Appelhans, David R Epstein, Maiken Keson-Brookes, Pablo J Cagnoni, Robert Langer and Ventures Fund Iv Gene Flagship.
View institutional ownership trends.

Shares of RUBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RUBY stock can currently be purchased for approximately $0.80.

Rubius Therapeutics (NASDAQ:RUBY) has a market capitalization of $72.28 million. The company earns $-196,550,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis.

The company employs 269 workers across the globe.

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The official website for the company is www.rubiustx.com. The company can be reached via phone at (617) 679-9600 or via email at ir@rubiustx.com.